Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.10% $1.400
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 68.66 mill |
EPS: | -0.170 |
P/E: | -8.24 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 49.05 mill |
Avg Daily Volume: | 0.0515 mill |
RATING 2024-04-18 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.24 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.40x |
Company: PE -8.24 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.054 (-24.70%) $-0.346 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 1.325 - 1.475 ( +/- 5.36%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-09 | Obrien Geoffrey | Buy | 84 000 | Employee Stock Option (Right to Buy) |
2024-01-09 | Matsuda Kazuko | Buy | 157 500 | Employee Stock Option (Right to Buy) |
2024-01-09 | Iwaki Yuichi | Buy | 210 000 | Employee Stock Option (Right to Buy) |
2023-08-04 | Lemerond Nicole | Buy | 18 333 | Stock Option (Right to Buy) |
2023-08-04 | Lemerond Nicole | Buy | 0 |
INSIDER POWER |
---|
98.70 |
Last 93 transactions |
Buy: 6 161 551 | Sell: 1 269 768 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.400 (-2.10% ) |
Volume | 0.0212 mill |
Avg. Vol. | 0.0515 mill |
% of Avg. Vol | 41.19 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.